Proteomic changes upon treatment with semaglutide in individuals with obesity
Open accessThe DOI matches its Crossref record; 69 of the 69 references it cites were found in a registry or an index.
Abstract
Obesity and type 2 diabetes are prevalent chronic diseases effectively managed by semaglutide. Here we studied the effects of semaglutide on the circulating proteome using baseline and end-of-treatment serum samples from two phase 3 trials in participants with overweight or obesity, with or without diabetes: STEP 1 ( n = 1,311) and STEP 2 ( n = 645). We identified evidence supporting broad effects of semaglutide, implicating processes related to body weight regulation, glycemic control, lipid metabolism and inflammatory pathways. Several proteins were regulated with semaglutide, after accounting for changes in body weight and HbA 1c at end of trial, suggesting effects of semaglutide on the proteome beyond weight loss and glucose lowering. A comparison of semaglutide with real-world proteomic profiles revealed potential benefits on disease-specific proteomic signatures including the downregulation of specific proteins associated with cardiovascular disease risk, supporting its reported effects of lowering cardiovascular disease risk and potential drug repurposing opportunities. This study showcases the potential of proteomics data gathered from randomized trials for providing insights into disease mechanisms and drug repurposing opportunities. These data also highlight the unmet need for, and importance of, examining proteomic changes in response to weight loss pharmacotherapy in future trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






![Extended Data Fig. 2 Pathways implicated by proteins affected by semaglutide treatment in STEP 1 (a) and STEP 2 (b). The figure shows the effect of semaglutide treatment (according to SomaScan®) on hallmark gene sets. Circle sizes visually indicate the number of proteins in a set (log2-scale). Black diamonds within the coloured circles indicate sets that are significantly affected by treatment (false discovery rate-adjusted P value [q value] < 0.05). Enrichment P values were computed using CameraPR. Results for the full list of gene sets are available in Supplementary Tables 9 and 10 for STEP 1 and STEP 2, respectively. KRAS, Kirsten rat sarcoma virus; MTORC1, mammalian target of rapamycin complex 1; MYC, myelocytomatosis oncogene.](https://figures.cochat.ai/paper-figures/78524e5e90914fd492d3802451e7b81a/proteomic-changes-upon-treatment-with-semaglutide-in-individuals-with-obesity-figure-7.jpg)
![Extended Data Fig. 3 Proteins increased by semaglutide treatment are implicated in the exocrine pancreas. Effect size was normalized using the means and standard deviations at baseline to compare results across proteins, with positive and negative values indicating that semaglutide increased and decreased protein levels; −log10(P values) indicate the level of significance of the effect size (approximately 500 proteins [approximately 8–10% of the measured proteome] were significant). The red dashed line shows the Bonferroni correction limit, and the blue dashed line shows the false discovery rate. Effect sizes and P values were computed using linear regression. AMY2A/2B, alpha-amylase 2 A/2B; CLPS, caseinolytic protease subunit S; CPB1, carboxypeptidase B1; EOT, end of treatment; PNLIPRP1/2, pancreatic lipase-related protein 1/2; PNLIP, pancreatic lipase; PRSS1/2/3, trypsin 1/2/3.](https://figures.cochat.ai/paper-figures/897c46915b344e819afb65bbca9a1055/proteomic-changes-upon-treatment-with-semaglutide-in-individuals-with-obesity-figure-8.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Proteomic analyses from the STEP weight loss trials in people with or without T2D revealed semaglutide-induced changes in inflammatory and immune regulatory pathways that could not be fully attributed to metabolic improvements alone (25).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [25]
The cited source says what the claim attributes to it.
In the citing paper
“Evidence from clinical trials suggests that GLP-1 medicines exert clinical benefits even in individuals who do not experience substantial weight loss (25).”
From Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits (2025) · cites this paper as [25]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Molecular Signatures Database Hallmark Gene Set Collection
Liberzon, A., Birger, C., Thorvaldsdóttir, H., Ghandi, M., Mesirov, J. P., & Tamayo, P. (2015) · Cell Systems · doi:10.1016/j.cels.2015.12.004 · Cited by 13,807
Murray, C. J. L., Aravkin, A. Y., Zheng, P., Abbafati, C., Abbas, K. M., Abbasi-Kangevari, M., Abd-Allah, F., Abdelalim, A., Abdollahi, M., Abdollahpour, I., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30752-2 · Cited by 9,854
An integrated map of genetic variation from 1,092 human genomes
The 1000 Genomes Project Consortium (2012) · Nature · doi:10.1038/nature11632 · Cited by 7,711
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 1×
“Several GLP-1RAs, including semaglutide, have been shown to offer cardiovascular outcome benefit in people with T2D 33–35 .”
Mendelian Randomization Analysis With Multiple Genetic Variants Using Summarized Data
Burgess, S., Butterworth, A., & Thompson, S. G. (2013) · Genetic Epidemiology · doi:10.1002/gepi.21758 · Cited by 6,050
Once-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205 · cited 4×
“A total of 3,171 male and female participants were included in the STEP 1 and STEP 2 trials; please refer to the published papers for full details 20,21 .”
InfluentialSemaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236 · cited 4×
“These benefits are now also evident in people with obesity at high CVD risk (or with known vascular disease) but without T2D, as shown by the favorable effects of semaglutide in the Semaglutide Effects on Heart Disease and Stroke in Patients with Overweight or Obesity (SELECT) clinical trial 36 .”
InfluentialGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163 · cited 1×
“Several GLP-1RAs, including semaglutide, have been shown to offer cardiovascular outcome benefit in people with T2D 33–35 .”
MINIMUM REDUNDANCY FEATURE SELECTION FROM MICROARRAY GENE EXPRESSION DATA
DING, C., & PENG, H. (2005) · Journal of Bioinformatics and Computational Biology · doi:10.1142/s0219720005001004 · Cited by 2,751
(2012) · Hepatogastroenterology · doi:10.5754/hge12458 · Cited by 1,977
Aptamer-Based Multiplexed Proteomic Technology for Biomarker Discovery
Gold, L., Ayers, D., Bertino, J., Bock, C., Bock, A., Brody, E. N., Carter, J., Dalby, A. B., Eaton, B. E., Fitzwater, T., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0015004 · Cited by 1,754 · cited 1×
“The SomaScan® aptamer-based proteomic platform was the first high-throughput platform used in large-scale studies 8 capable of simultaneously measuring the relative abundance of thousands of proteins from small sample volumes.”
Large-scale integration of the plasma proteome with genetics and disease
Ferkingstad, E., Sulem, P., Atlason, B. A., Sveinbjornsson, G., Magnusson, M. I., Styrmisdottir, E. L., Gunnarsdottir, K., Helgason, A., Oddsson, A., Halldorsson, B. V., et al. (2021) · Nature Genetics · doi:10.1038/s41588-021-00978-w · Cited by 1,697 · cited 4×
“Comparisons with proteomic profiles identified in the deCODE cohort (an observational cohort of 35,559 Icelanders 23 ) allowed us to examine where semaglutide treatment might have benefits and assess its potential impact on a wide range of conditions, including CVD (atherosclerotic myocardial…”
InfluentialSemaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669 · cited 1×
“Indeed, data from STEP-HFpEF and STEP-HFpEF DM trials have shown a significant reduction in inflammatory markers such as CRP with semaglutide compared with placebo 45,46 .”
2. Classification and Diagnosis of Diabetes
American Diabetes Association (2017) · Diabetes Care · doi:10.2337/dc17-s005 · Cited by 1,603
Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599
Long-term persistence of hormonal adaptations to weight loss
Sumithran, P., Prendergast, L. A., Delbridge, E., Purcell, K., Shulkes, A., Kriketos, A., & Proietto, J. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105816 · Cited by 1,449 · cited 1×
“…loss due to a very-low-energy diet (VLED) resulted in counter-regulatory changes in appetite-regulating hormones, including a significant increase in fasting levels of ghrelin and significant reductions in the fasting levels of leptin, GLP-1, peptide YY (PYY), cholecystokinin (CCK) and amylin 48 .”
Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00213-0 · Cited by 1,419 · cited 3×
“A total of 3,171 male and female participants were included in the STEP 1 and STEP 2 trials; please refer to the published papers for full details 20,21 .”
InfluentialBhaskaran, K., dos-Santos-Silva, I., Leon, D. A., Douglas, I. J., & Smeeth, L. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(18)30288-2 · Cited by 1,228 · cited 1×
“This makes obesity one of the leading risk factors for multimorbidity 2 , negatively impacting metabolic, cardio-vascular (CV), mental and physical health, as well as mortality 3,4 .”
Pulit, S. L., Stoneman, C., Morris, A. P., Wood, A. R., Glastonbury, C. A., Tyrrell, J., Yengo, L., Ferreira, T., Marouli, E., Ji, Y., et al. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddy327 · Cited by 1,163
Camera: a competitive gene set test accounting for inter-gene correlation
Wu, D., & Smyth, G. K. (2012) · Nucleic Acids Research · doi:10.1093/nar/gks461 · Cited by 891
Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial
Garvey, W. T., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2022) · Nature Medicine · doi:10.1038/s41591-022-02026-4 · Cited by 868 · cited 2×
“Semaglutide is known to improve satiety and reduce cravings for savory food, as well as improve the control of eating 49 , resulting in sustained weight loss over 104 weeks 50 .”
Semaglutide in Patients with Obesity-Related Heart Failure and Type 2 Diabetes
Kosiborod, M. N., Petrie, M. C., Borlaug, B. A., Butler, J., Davies, M. J., Hovingh, G. K., Kitzman, D. W., Møller, D. V., Treppendahl, M. B., Verma, S., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2313917 · Cited by 758 · cited 1×
“Indeed, data from STEP-HFpEF and STEP-HFpEF DM trials have shown a significant reduction in inflammatory markers such as CRP with semaglutide compared with placebo 45,46 .”
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717 · cited 1×
“However, GLP-1RAs also have separate effects on appetite regulation mediated by actions on central nervous system centers that result in weight loss 15,16 .”
Self-citationMahajan, A., Spracklen, C. N., Zhang, W., Ng, M. C. Y., Petty, L. E., Kitajima, H., Yu, G. Z., Rüeger, S., Speidel, L., Kim, Y. J., et al. (2022) · Nature Genetics · doi:10.1038/s41588-022-01058-3 · Cited by 704
Kivimäki, M., Strandberg, T., Pentti, J., Nyberg, S. T., Frank, P., Jokela, M., Ervasti, J., Suominen, S. B., Vahtera, J., Sipilä, P. N., et al. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00033-x · Cited by 628 · cited 1×
“This makes obesity one of the leading risk factors for multimorbidity 2 , negatively impacting metabolic, cardio-vascular (CV), mental and physical health, as well as mortality 3,4 .”
Proteomics: Challenges, Techniques and Possibilities to Overcome Biological Sample Complexity
Chandramouli, K., & Qian, P.-Y. (2009) · Human Genomics and Proteomics · doi:10.4061/2009/239204 · Cited by 511 · cited 1×
“Proteomics is the large-scale study of the structure and function of proteins 6 using high-throughput platforms.”
Prevalence of Alcohol Use Disorders Before and After Bariatric Surgery
King, W. C., Chen, J.-Y., Mitchell, J. E., Kalarchian, M. A., Steffen, K. J., Engel, S. G., Courcoulas, A. P., Pories, W. J., & Yanovski, S. Z. (2012) · JAMA · doi:10.1001/jama.2012.6147 · Cited by 509 · cited 7×
“However, it is important to highlight that the GBS study used an older version of the SomaScan® assay that included a smaller number of proteomic markers (1,297), and that the comparison used 2 year post-GBS data versus the 1-year follow-up data in the STEP trials.”
InfluentialFriedrichsen, M., Breitschaft, A., Tadayon, S., Wizert, A., & Skovgaard, D. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14280 · Cited by 427 · cited 1×
“However, GLP-1RAs also have separate effects on appetite regulation mediated by actions on central nervous system centers that result in weight loss 15,16 .”
Aroda, V. R., Ahmann, A., Cariou, B., Chow, F., Davies, M. J., Jódar, E., Mehta, R., Woo, V., & Lingvay, I. (2019) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.12.001 · Cited by 296 · cited 1×
“Approval was based on the action of GLP-1 receptor agonists (GLP-1RAs) to lower glycated hemoglobin (HbA 1c ) levels by increasing glucose-dependent insulin release, reducing glucagon secretion and delaying gastric emptying 13,14 .”
Intentional and Unintentional Nonadherence: A Study of Decision Making
Wroe, A. L. (2002) · Journal of Behavioral Medicine · doi:10.1023/a:1015866415552 · Cited by 283 · cited 1×
“Article https://doi.org/10.1038/s41591-024-03355-2 The proteomic signature of semaglutide could possibly serve to assess intentional and nonintentional nonadherence with prescribed treatment, especially in those with modest weight loss 47 .”
InfluentialArcuate Nucleus-Dependent Regulation of Metabolism—Pathways to Obesity and Diabetes Mellitus
Jais, A., & Brüning, J. C. (2022) · Endocrine Reviews · doi:10.1210/endrev/bnab025 · Cited by 280 · cited 1×
“…of GLP-1 receptors; for example, in the hypothalamus, semaglutide affects the pro-opiomelanocortin and cocaine-and amphetamine-regulated transcript (POMC/CART) and neuropeptide Y and Agouti-related protein (NPY/AGRP) neurons known to suppress appetite and stimulate food intake, respectively 51–53 .”
The NPY/AgRP neuron and energy homeostasis
Morton, G., & Schwartz, M. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801915 · Cited by 261
Li, L., Shen, J., Bala, M. M., Busse, J. W., Ebrahim, S., Vandvik, P. O., Rios, L. P., Malaga, G., Wong, E., Sohani, Z., et al. (2014) · BMJ · doi:10.1136/bmj.g2366 · Cited by 254 · cited 2×
“In addition, previous systematic reviews and meta-analyses have shown that GLP-1RA treat-ment in people with T2D was not associated with increased risk of pancreatitis 27,28 or pancreatic cancer 28,29 .”
Mahdi, T., Hänzelmann, S., Salehi, A., Muhammed, S. J., Reinbothe, T. M., Tang, Y., Axelsson, A. S., Zhou, Y., Jing, X., Almgren, P., et al. (2012) · Cell Metabolism · doi:10.1016/j.cmet.2012.10.009 · Cited by 193 · cited 1×
“61,62)) and metabolic-associated steatohepatitis (LFABP 63 ).”
Abd El Aziz, M., Cahyadi, O., Meier, J. J., Schmidt, W. E., & Nauck, M. A. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13924 · Cited by 160 · cited 1×
“In addition, previous systematic reviews and meta-analyses have shown that GLP-1RA treat-ment in people with T2D was not associated with increased risk of pancreatitis 27,28 or pancreatic cancer 28,29 .”
NTproBNP: An Important Biomarker in Cardiac Diseases
Panagopoulou, V., Deftereos, S. G., Kossyvakis, C., Raisakis, K., Γιαννόπουλος, Γ., Bouras, G., Pyrgakis, V. N., & CLEMAN, M. W. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611313020002 · Cited by 149 · cited 1×
“…after adjusting for effects of weight loss and HbA 1c reduction) include NPPB (NT-proBNP, released from cardiomyocytes on ventricular distension) 37 , ANGPT2 (involved in vascular remodeling and angiogenesis) 38 , CD93 (involved in cardiovascular homeostasis) 39 , MSR1 (involved in lipid…”
Efficacy of semaglutide in a subcutaneous and an oral formulation
Meier, J. J. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.645617 · Cited by 146
Wang, W., Volkow, N. D., Berger, N. A., Davis, P. B., Kaelber, D. C., & Xu, R. (2024) · Nature Communications · doi:10.1038/s41467-024-48780-6 · Cited by 135 · cited 3×
“…propensity-score-matched study of 83,825 patients with obesity, which showed that semaglutide, compared with other non-GLP-1-based obesity medications, was associated with a 50% lower risk for incident and recurrent alcohol use disorders over a 12-month period regardless of T2D status 24 .”
InfluentialBenefits of weight loss of 10% or more in patients with overweight or obesity: A review
Tahrani, A. A., & Morton, J. (2022) · Obesity · doi:10.1002/oby.23371 · Cited by 125 · cited 1×
“Recent advances in achieving weight loss through lifestyle behavioral interventions, pharmacotherapy, metabolic bariatric surgery or a combination of these effectively reduce the economic and health impact of obesity and improve the quality of life of affected individuals 5 .”
Self-citationTwo‐year effect of semaglutide 2.4 mg on control of eating in adults with overweight/obesity: STEP 5
Wharton, S., Batterham, R. L., Bhatta, M., Buscemi, S., Christensen, L. N., Frias, J. P., Jódar, E., Kandler, K., Rigas, G., Wadden, T. A., et al. (2023) · Obesity · doi:10.1002/oby.23673 · Cited by 124 · cited 2×
“Semaglutide is known to improve satiety and reduce cravings for savory food, as well as improve the control of eating 49 , resulting in sustained weight loss over 104 weeks 50 .”
Williams, S. A., Ostroff, R., Hinterberg, M. A., Coresh, J., Ballantyne, C. M., Matsushita, K., Mueller, C. E., Walter, J., Jonasson, C., Holman, R. R., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj9625 · Cited by 97 · cited 2×
“Consistent with this, semaglutide treatment favorably reduced the cardiovascular disease 2 (CVD2) risk score calculated using a 27-protein proteomic model 22 .”
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Christensen, L., Davies, M., Hovingh, K. G., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · JACC: Heart Failure · doi:10.1016/j.jchf.2023.05.010 · Cited by 97 · cited 1×
“This has been evaluated in the STEP-HFpEF (people with obesity and HFpEF without diabetes) and STEP-HFpEF DM (people with obesity and HFpEF with T2D) trials 44 .”
Yu, H., Ha, T., Liu, L., Wang, X., Gao, M., Kelley, J., Kao, R., Williams, D., & Li, C. (2012) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2012.05.004 · Cited by 91 · cited 1×
“…cardiomyocytes on ventricular distension) 37 , ANGPT2 (involved in vascular remodeling and angiogenesis) 38 , CD93 (involved in cardiovascular homeostasis) 39 , MSR1 (involved in lipid metabolism and immune function) 40,41 , and THBS2 and TNC (both involved in extracellular matrix remodeling) 42 .”
Steinberg, W. M., Buse, J. B., Ghorbani, M. L. M., Ørsted, D. D., Nauck, M. A., the LEADER Steering Committee, & on behalf of the LEADER Trial Investigators (2017) · Diabetes Care · doi:10.2337/dc16-2747 · Cited by 87 · cited 1×
“In the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) trial evaluating liraglutide (a GLP-1 analog), the observed mild elevations in pancreatic enzyme were not predictive of subsequent acute pancreatitis 26 .”
Pinto, L. C., Falcetta, M. R., Rados, D. V., Leitão, C. B., & Gross, J. L. (2019) · Scientific Reports · doi:10.1038/s41598-019-38956-2 · Cited by 84 · cited 1×
“In addition, previous systematic reviews and meta-analyses have shown that GLP-1RA treat-ment in people with T2D was not associated with increased risk of pancreatitis 27,28 or pancreatic cancer 28,29 .”
Steinberg, W. M., Rosenstock, J., Wadden, T. A., Donsmark, M., Jensen, C. B., & DeVries, J. H. (2017) · Diabetes Care · doi:10.2337/dc16-2684 · Cited by 76 · cited 1×
“Such increases rarely exceed the upper normal limit and are reversible after treatment discontinuation 25 .”
Microglial Progranulin: Involvement in Alzheimer’s Disease and Neurodegenerative Diseases
Mendsaikhan, A., Tooyama, I., & Walker, D. G. (2019) · Cells · doi:10.3390/cells8030230 · Cited by 72
Angiopoietin 2 signal complexity in cardiovascular disease and cancer
Nicolini, G., Forini, F., Kusmic, C., Iervasi, G., & Balzan, S. (2019) · Life Sciences · doi:10.1016/j.lfs.2019.117080 · Cited by 63 · cited 1×
“…include NPPB (NT-proBNP, released from cardiomyocytes on ventricular distension) 37 , ANGPT2 (involved in vascular remodeling and angiogenesis) 38 , CD93 (involved in cardiovascular homeostasis) 39 , MSR1 (involved in lipid metabolism and immune function) 40,41 , and THBS2 and TNC (both…”
Van Eck, M., De Winther, M. P. J., Herijgers, N., Havekes, L. M., Hofker, M. H., Groot, P. H. E., & Van Berkel, T. J. C. (2000) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.20.12.2600 · Cited by 63 · cited 1×
“…cardiomyocytes on ventricular distension) 37 , ANGPT2 (involved in vascular remodeling and angiogenesis) 38 , CD93 (involved in cardiovascular homeostasis) 39 , MSR1 (involved in lipid metabolism and immune function) 40,41 , and THBS2 and TNC (both involved in extracellular matrix remodeling) 42 .”
Proteomics in the pharmaceutical and biotechnology industry: a look to the next decade
Lill, J. R., Mathews, W. R., Rose, C. M., & Schirle, M. (2021) · Expert Review of Proteomics · doi:10.1080/14789450.2021.1962300 · Cited by 59 · cited 1×
“Examples of the relative abundance of specific proteins at baseline and week response and disease progression, and identification of novel therapeutic targets 7 .”
Plasma Proteomics of COVID-19–Associated Cardiovascular Complications
Roh, J. D., Kitchen, R. R., Guseh, J. S., McNeill, J. N., Aïd, M., Martinot, A. J., Yu, A., Platt, C., Rhee, J., Weber, B., et al. (2022) · JACC Basic to Translational Science · doi:10.1016/j.jacbts.2022.01.013 · Cited by 53
Gene Expression and the Control of Food Intake by Hypothalamic POMC/CART Neurons.
Hill, J. W. (2010) · PubMed · Cited by 49
Sakamuri, S. S. V. P., Watts, R., Takawale, A. R., Wang, X., Hernandez‐Anzaldo, S., Bahitham, W., Fernández-Patrón, C., Lehner, R. S., & Kassiri, Z. (2017) · Scientific Reports · doi:10.1038/s41598-017-05951-4 · Cited by 48 · cited 1×
“Absence of TIMP4 ameliorated high-fat-diet-induced obesity in mice 30 .”
Purnell, J. Q., Johnson, G., Wahed, A. S., Man, C. D., Piccinini, F., Cobelli, C., Prigeon, R. L., Goodpaster, B. H., Kelley, D. E., Staten, M. A., et al. (2018) · Diabetologia · doi:10.1007/s00125-018-4553-y · Cited by 43 · cited 7×
“However, it is important to highlight that the GBS study used an older version of the SomaScan® assay that included a smaller number of proteomic markers (1,297), and that the comparison used 2 year post-GBS data versus the 1-year follow-up data in the STEP trials.”
InfluentialSelf-citationFigarska, S. M., Rigdon, J., Ganna, A., Elmståhl, S., Lind, L., Gardner, C. D., & Ingelsson, E. (2020) · Scientific Reports · doi:10.1038/s41598-020-64636-7 · Cited by 42 · cited 1×
“Weight loss following dietary interventions and bariatric surgery is associated with changes to the circulating proteome, including proteins related to inflammatory and metabolic pathways 9,10 .”
Dreyfuss, J. M., Yuchi, Y., Dong, X., Efthymiou, V., Pan, H., Simonson, D. C., Vernon, A. H., Halperin, F., Aryal, P., Konkar, A. A., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-27289-2 · Cited by 39 · cited 1×
“Weight loss following dietary interventions and bariatric surgery is associated with changes to the circulating proteome, including proteins related to inflammatory and metabolic pathways 9,10 .”
Secreted frizzled‐related protein 4 and its implication in obesity and type‐2 diabetes
Bukhari, S. A., Yasmin, A., Zahoor, M. A., Mustafa, G., Sarfraz, I., & Rasul, A. (2019) · IUBMB Life · doi:10.1002/iub.2123 · Cited by 37 · cited 1×
“61,62)) and metabolic-associated steatohepatitis (LFABP 63 ).”
Serum liver fatty acid binding protein shows good correlation with liver histology in NASH.
Özeni̇rler, S., Değertekin, C. K., Erkan, G., Elbeğ, Ş., Tunçer, C., Kandilc, U., & Akyol, G. (2013) · PubMed · doi:10.5754/hge11949 · Cited by 27
The Role of Matrix Proteins in Cardiac Pathology
Trinh, K., Julovi, S. M., & Rogers, N. M. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23031338 · Cited by 25 · cited 1×
“…cardiomyocytes on ventricular distension) 37 , ANGPT2 (involved in vascular remodeling and angiogenesis) 38 , CD93 (involved in cardiovascular homeostasis) 39 , MSR1 (involved in lipid metabolism and immune function) 40,41 , and THBS2 and TNC (both involved in extracellular matrix remodeling) 42 .”
Lugano, R., Vemuri, K., Barbera, S., Orlandini, M., Dejana, E., Claesson, L., & Dimberg, A. (2023) · The FASEB Journal · doi:10.1096/fj.202201623rr · Cited by 25 · cited 1×
“…cardiomyocytes on ventricular distension) 37 , ANGPT2 (involved in vascular remodeling and angiogenesis) 38 , CD93 (involved in cardiovascular homeostasis) 39 , MSR1 (involved in lipid metabolism and immune function) 40,41 , and THBS2 and TNC (both involved in extracellular matrix remodeling) 42 .”
Mao, Q., Wang, D., Li, Y., Kohler, M., Wilson, J., Parton, Z., Shmaltsuyeva, B., Gursel, D., Rademakers, R., Weintraub, S., et al. (2017) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlx085 · Cited by 24 · cited 1×
“In addition to the effects beyond weight loss of semaglutide on proteins related to CVD (as discussed above), other significantly regulated proteins in this analysis have previously been implicated in other conditions such as Alzheimer’s disease (TNC 58 , granulin 59,60 ), T2D (sFRP4 (refs.”
Proteomic Profiles of Body Mass Index and Waist-to-Hip Ratio and Their Role in Incidence of Diabetes
Bao, X., Xu, B., Yin, S., Pan, J., Nilsson, P. M., Nilsson, J. Å., Melander, O., Orho‐Melander, M., & Engström, G. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac140 · Cited by 22 · cited 1×
“Third, several of the differentially expressed proteins identified in our study have also been associated with BMI in a previously published observational study using the Olink affinity-based assay 64 , which supports our findings.”
Combined Whole Methylome and Genomewide Association Study ImplicatesCNTN4in Alcohol Use
Clark, S. L., Åberg, K. A., Nerella, S., Kumar, G., McClay, J. L., Chen, W., Xie, L., Harada, A., Shabalin, A. A., Gao, G., et al. (2015) · Alcoholism Clinical and Experimental Research · doi:10.1111/acer.12790 · Cited by 20 · cited 1×
“CNTN4 has been described as a risk factor for alcohol use 56 , and increased alcohol use disorder has been widely reported after GBS 57 .”
Genetic Predictors of ≥5% Weight Loss by Multidisciplinary Advice to Severely Obese Subjects
Aller, E. E. J. G., Mariman, E. C. M., Bouwman, F. G., & van Baak, M. A. (2017) · Lifestyle Genomics · doi:10.1159/000469662 · Cited by 19
Hasanzadeh, Z., Nourazarian, A., Nikanfar, M., Laghousi, D., Vatankhah, A. M., & Sadrirad, S. (2020) · Journal of Molecular Neuroscience · doi:10.1007/s12031-020-01710-9 · Cited by 15 · cited 1×
“In addition to the effects beyond weight loss of semaglutide on proteins related to CVD (as discussed above), other significantly regulated proteins in this analysis have previously been implicated in other conditions such as Alzheimer’s disease (TNC 58 , granulin 59,60 ), T2D (sFRP4 (refs.”
Chen, C.-C., Geng, J., Wu, P.-Y., Huang, J., Hu, H., Chen, S., & Kuo, C. (2024) · Obesity Facts · doi:10.1159/000540281 · Cited by 13
Yousri, N. A., Engelke, R., Sarwath, H., McKinlay, R. D., Simper, S. C., Adams, T. D., Schmidt, F. M., Suhre, K., & Hunt, S. C. (2021) · Obesity · doi:10.1002/oby.23303 · Cited by 9 · cited 7×
“However, it is important to highlight that the GBS study used an older version of the SomaScan® assay that included a smaller number of proteomic markers (1,297), and that the comparison used 2 year post-GBS data versus the 1-year follow-up data in the STEP trials.”
InfluentialProteomic Pathways across Ejection Fraction Spectrum in Heart Failure: an EXSCEL SubstudyPreprint
Peters, A. E., Nguyen, M., Green, J. B., Pearson, E. R., Buse, J. B., Sourij, H., Hernandez, A. F., Sattar, N. A., Holman, R. R., Mentz, R. J., et al. (2023) · medRxiv · doi:10.1101/2023.05.16.23288273 · Cited by 7 · cited 1×
“Previous results indicate that TNC is downregulated by GLP-1RA treatment and correlates with incident CVD 43 , suggesting that TNC may act as a mediator, with downregulation contributing to the cardiovascular-protective effects of GLP-1RAs.”
Proteomic changes upon treatment with semaglutide in individuals with obesity
Maretty, L., Gill, D., Simonsen, L., Soh, K., Zagkos, L., Galanakis, M., Sibbesen, J. A., Iglesias, M., Secher, A., Valkenborg, D., et al. (2025) · Document Server@UHasselt (UHasselt) · doi:10.5281/zenodo.13356054 · Cited by 2
Self-citation
Cited by
Antiinflammatory actions of glucagon-like peptide-1–based therapies beyond metabolic benefits
Wong, C. K., & Drucker, D. J. (2025) · Journal of Clinical Investigation · doi:10.1172/jci194751 · Cited by 112
Obesity, diabetes, and inflammation: Pathophysiology and clinical implications
Donath, M. Y., & Drucker, D. J. (2025) · Immunity · doi:10.1016/j.immuni.2025.09.011 · Cited by 69
The expanding landscape of GLP-1 medicines
Drucker, D. J. (2026) · Nature Medicine · doi:10.1038/s41591-025-04124-5 · Cited by 82
“…therapy with either 2 mg exenatide once weekly in the EXSCEL trial 48 , or with 2.4 mg QW semaglutide in the STEP-1 and STEP-2 weight loss trials 49 , revealed reductions in circulating biomarkers of inflammation that also serve as indirect proxies for neuroinflammation in people with…”
InfluentialAdvances in GLP-1 receptor agonists for pain treatment and their future potential
He, Y., Xu, B., Zhang, M., Chen, D., Wu, S., Gao, J., Liu, Y., Zhang, Z., Kuang, J., & Fang, Q. (2025) · The Journal of Headache and Pain · doi:10.1186/s10194-025-01979-4 · Cited by 46
“In a recent 2025 study using large-scale proteomic analysis of serum samples from two phase 3 clinical trials, Maretty et al. demonstrated that semaglutide modulates the circulating proteome in individuals with overweight or obesity, with or without diabetes [67].”
InfluentialGlucagon-like peptide-1 receptor agonists for major neurocognitive disorders
Giorgi, R. D., Ghenciulescu, A., Yotter, C. N., Taquet, M., & Koychev, I. G. (2025) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2024-335593 · Cited by 47
“20 From a mechanistic perspective, however, most evidence regarding the putative neuroprotective activity of GLP-1RAs stems from preclinical, that is, in vitro or animal models.”
Influential
Metadata
- Authors
- Maretty, L., Gill, D., Simonsen, L., Soh, K., Zagkos, L., Galanakis, M., Sibbesen, J., Iglesias, M. T., Secher, A., Valkenborg, D., Purnell, J. Q., Knudsen, L. B., Tahrani, A. A., & Geybels, M.
- Affiliations
- Novo Nordisk (Denmark) (DK)
- Imperial College London (GB)
- Hasselt University (BE)
- Oregon Health & Science University (US)
- Corresponding author
- Tahrani, Abd A.
- ORCID
- Venue
- Nature Medicine
- Published
- 2025-01
- Volume
- 31
- Issue
- 1
- Pages
- 267-277
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC11750704
- OpenAlex
- W4406051813
- Cited by
- 86
- References
- 69
- Citations by year
- 2026: 52 · 2025: 33
- FWCI
- 47.71
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor, 2 d)
- Locations
- Nature Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (publishedVersion, cc-by)
- Document Server@UHasselt (UHasselt) (submittedVersion, other-oa)
- Funders
- Novo Nordisk A/S
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Keywords
- semaglutide, obesity, type 2 diabetes, circulating proteome, serum proteins, pharmacological weight loss, glycemic control, lipid metabolism, inflammation, cardiovascular risk, drug repurposing
- MeSH terms
- Semaglutide, Adult, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Female, Glycated Hemoglobin, Humans, Male, Middle Aged, Obesity, Weight Loss, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic, Proteome, Proteomics, Glucagon-Like Peptide 1, Observational Studies as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.